

## Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026

Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a summary of the resolutions made. All resolutions were passed with the required majority.

### Resolution regarding the adoption of the accounts and allocation of the Company's result

The annual general meeting resolved to adopt the profit and loss statement and the balance sheet. The annual general meeting also resolved to allocate the Company's result in accordance with the board of directors' and the CEO's proposal, meaning that no dividend is paid to the shareholders, and that available funds are carried forward.

### Discharge from liability for the members of the board of directors and the managing director

The annual general meeting resolved to grant discharge from liability to the members of the board of directors and the managing director for the financial year 2025.

### Election of and remuneration to the board of directors and the auditor

The annual general meeting resolved, in accordance with the nomination committees' proposal, on re-election of Ragnar Linder, Janet Hoogstraate, Eva Lilienberg and Jan Lundberg as ordinary members of the board of directors. Eggert Mörling was, in accordance with the nomination committee's proposal, elected as a new member of the board, and as chairman of the board of directors. Thomas Pollare has declined re-election.

The annual general meeting further resolved that the remuneration to the board of directors shall be SEK 400,000 to the chairman and SEK 200,000 to each of the other board members who are not employed by the Company.

The annual general meeting also resolved to, in accordance with the nomination committees' proposal, re-elect Grant Thornton AB as auditor and that the auditor shall be paid according to approved invoice. Grant Thornton AB has announced that the certified accountant Camilla Nilsson will be the auditor in charge.

### Resolution on the approval of the remuneration report

The annual general meeting resolved to approve the board of director's remuneration report in accordance with Chapter 8, Section 53 a of the Swedish Companies Act.

### Authorisation for the board of directors to resolve on new issues

The annual general meeting resolved, in accordance with the board of directors' proposal, to authorise the board of directors, on one or more occasions during the period until the next annual general meeting, with or without deviation from the shareholders' pre-emptive right, to resolve on new issues of shares, warrants and/or convertibles that means issuing, subscribing to or converting a number of shares corresponding to a maximum dilution of 20 per cent of the total number of shares in the Company at the time of the resolution. The new issues can be carried out with or without a provision regarding contribution in kind, set-off or other provisions referred to in Chapter 13, Section 5, first paragraph 6, Chapter 14, Section 5, first paragraph 6 and Chapter 15, Section 5, first paragraph 4, of the Swedish Companies Act.

The purpose of the authorisation is to increase the Company's financial flexibility and the board of directors' scope of action. The board of directors, or any other person that they appoint, shall be authorized to make such minor adjustments and clarifications to the resolution that may be required in relation to the registration of the resolution by the Swedish Companies Registration Office.

The board of directors' and nomination committee's complete proposals and other documentation in connection with the annual general meeting are available on the Company's website [www.alzecurepharma.com](http://www.alzecurepharma.com) where the minutes from the annual general meeting will also be posted.

### For more information, please contact

---

Martin Jönsson, CEO  
Tel: +46(0)76 767 50 77  
[martin.jonsson@alzecurepharma.com](mailto:martin.jonsson@alzecurepharma.com)

### About AlzeCure Pharma AB (publ)

---

AlzeCure® is a Swedish clinical stage biotech company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of one symptomatic drug candidate where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. NeuroRestore has received an EU grant from the European Innovation Council and is being prepared for phase 2. Painless contains two projects: ACD440, which is a drug candidate for the treatment of neuropathic pain with positive phase 2 results and orphan drug designation from the FDA in the USA and from EMA in Europe for the rare pain disease erythromelalgia, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. Within the Alzstatin platform, the company has entered into a collaboration and out-licensing agreement with Lilly regarding the global rights to the Alzheimer's project Alzstatin ACD680. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit [www.alzecurepharma.se](http://www.alzecurepharma.se).

### Attachments

---

Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026